



RESEARCH ARTICLE

ANXIETY AND DEPRESSION
ASSOCIATION OF AMERICA WILEY

Perceived helpfulness of treatment for posttraumatic stress disorder: Findings from the World Mental Health Surveys

Dan J. Stein¹ | Meredith G. Harris^{2,3} | Daniel V. Vigo^{4,5} | Wai Tat Chiu⁶ |
Nancy Sampson⁶ | Jordi Alonso^{7,8,9} | Yasmin Altwajri¹⁰ | Brendan Bunting¹¹ |
José Miguel Caldas-de-Almeida¹² | Alfredo Cía¹³ | Marius Ciutan¹⁴ |
Louisa Degenhardt¹⁵ | Oye Gureje¹⁶ | Aimee Karam¹⁷ | Elie G. Karam^{17,18} |
Sing Lee¹⁹ | Maria Elena Medina-Mora²⁰ | Zeina Mneimneh²¹ |
Fernando Navarro-Mateu^{22,23,24} | José Posada-Villa²⁵ | Charlene Rapsey²⁶ |
Yolanda Torres²⁷ | Maria Carmen Viana²⁸ | Yuval Ziv²⁹ | Ronald C. Kessler⁶ |
the WHO World Mental Health Survey Collaborators

¹Department of Psychiatry & Mental Health and South African Medical Council Research Unit on Risk and Resilience in Mental Disorders, University of Cape Town and Groote Schuur Hospital, Cape Town, Republic of South Africa

²School of Public Health, The University of Queensland, Herston, Australia

³Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Brisbane, Australia

⁴Department of Psychiatry, University of British Columbia, Vancouver, Canada

⁵Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts

⁶Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts

⁷Health Services Research Unit, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain

⁸Pompeu Fabra University (UPF), Barcelona, Spain

⁹CIBER en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain

¹⁰Epidemiology Section, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

¹¹School of Psychology, Ulster University, Londonderry, United Kingdom

¹²Lisbon Institute of Global Mental Health and Chronic Diseases Research Center (CEDOC), NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal

¹³Anxiety Disorders Center, Buenos Aires, Argentina

¹⁴National School of Public Health, Management and Professional Development, Bucharest, Romania

¹⁵National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia

¹⁶Department of Psychiatry, University College Hospital, Ibadan, Nigeria

¹⁷Institute for Development, Research, Advocacy & Applied Care (IDRAAC), Beirut, Lebanon

¹⁸Department of Psychiatry and Clinical Psychology, St George Hospital University Medical Center, Faculty of Medicine, Balamand University, Beirut, Lebanon

¹⁹Department of Psychiatry, Chinese University of Hong Kong, Tai Po, Hong Kong

²⁰National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico City, Mexico

²¹Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, Michigan

²²UDIF-SM, Servicio Murciano de Salud, Murcia, Spain

²³IMIB-Arrixaca, Murcia, Spain

²⁴CIBERESP-Murcia, Región de Murcia, Spain

²⁵Faculty of Social Sciences, Colegio Mayor de Cundinamarca University, Bogota, Colombia

²⁶Department of Psychological Medicine, University of Otago, Dunedin, New Zealand

²⁷Center for Excellence on Research in Mental Health, CES University, Medellín, Colombia

²⁸Department of Social Medicine, Postgraduate Program in Public Health, Federal University of Espírito Santo, Vitoria, Brazil

²⁹Mental Health Services, Israeli Ministry of Health, Jerusalem, Israel

Correspondence

Ronald C. Kessler, Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA 02115.

Email: kessler@hcp.med.harvard.edu

Funding information

Saudi Basic Industries Corporation (SABIC); National Insurance Institute of Israel; King Abdulaziz City for Science and Technology (KACST); Israel National Institute for Health Policy and Health Services Research; Secretary of Health of Medellín; Eli Lilly Romania SRL; Ministry of Public Health, Romania; Eli Lilly and Company; World Health Organization; World Health Organization (Nigeria); Ortho-McNeil Pharmaceutical Inc.; Fogarty International Center, Grant/Award Number: FIRCA R03-TW006481; Ministry of Health, New Zealand; Pan American Health Organization; Health & Social Care Research & Development Division of the Public Health Agency; Pfizer; Australian Government Department of Health and Ageing; State of São Paulo Research Foundation (FAPESP), Grant/Award Number: 03/00204-3; GlaxoSmithKline; Federal Ministry of Health, Abuja, Nigeria; Ministerio de Salud de la Nación, Grant/Award Number: 2002-17270/13 - 5; Bristol-Myers Squibb; National Institute of Mental Health, Grant/Award Numbers: R01 MH070884, U01-MH60220; National Institute of Psychiatry Ramon de la Fuente, Grant/Award Number: INPRFMIDIES 4280; UPO; John D. and Catherine T. MacArthur Foundation; National Council on Science and Technology, Grant/Award Number: CONACyT-G30544- H; Ministry of Social Protection, Colombia; Substance Abuse and Mental Health Services Administration; OmniPharma; Phencia; Novartis; King Faisal Specialist Hospital and Research Center; National Institute of Health / Fogarty International Center, Grant/Award Number: R03 TW006481-01; Saudi Arabia Ministry of Economy and Planning, General Authority for Statistics; Algorithm; IDRAAC, Lebanon; Ministry of Health, Saudi Arabia; King Saud University; Japan Ministry of Health, Labour and Welfare, Grant/Award Numbers: H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013, H25-SEISHIN-IPPAN-006; Ministry of Economy and Planning, General Authority for Statistics, Saudi Arabia; Lebanese Ministry of Public Health; Ministry of Health, Bulgaria; National Center for Public Health Protection, Bulgaria; Lundbeck; Fundación para la Formación e Investigación Sanitarias de la Región de Murcia; AstraZeneca; Bella Pharma; Comunidad Autónoma de la Región de Murcia; Benta; Foundation for Science and Technology (FCT); Center for Excellence on Research in Mental Health (CES University); Ministry of Health, Portugal; Calouste Gulbenkian

Abstract

Background: Perceived helpfulness of treatment is an important healthcare quality indicator in the era of patient-centered care. We examine probability and predictors of two key components of this indicator for posttraumatic stress disorder (PTSD).

Methods: Data come from World Mental Health surveys in 16 countries. Respondents who ever sought PTSD treatment ($n = 779$) were asked if treatment was ever helpful and, if so, the number of professionals they had to see to obtain helpful treatment. Patients whose treatment was never helpful were asked how many professionals they saw. Parallel survival models were estimated for obtaining helpful treatment in a specific encounter and persisting in help-seeking after earlier unhelpful encounters.

Results: Fifty seven percent of patients eventually received helpful treatment, but survival analysis suggests that it would have been 85.7% if all patients had persisted in help-seeking with up to six professionals after earlier unhelpful treatment. Survival analysis suggests that only 23.6% of patients would persist to that extent. Odds of ever receiving helpful treatment were positively associated with receiving treatment from a mental health professional, short delays in initiating help-seeking after onset, absence of prior comorbid anxiety disorders and childhood adversities, and initiating treatment before 2000. Some of these variables predicted helpfulness of specific treatment encounters and others predicted persistence after earlier unhelpful encounters.

Conclusions: The great majority of patients with PTSD would receive treatment they considered helpful if they persisted in help-seeking after initial unhelpful encounters, but most patients whose initial treatment is unhelpful give up before receiving helpful treatment.

KEYWORDS

cross national, epidemiology, health services, PTSD, trauma, treatment

Foundation; EEA Grants; Champalimaud Foundation; Ministry of Health, State of Israel; National Institute of Drug Abuse (NIDA); Servier; World Health Organization (Lebanon); Alcohol Advisory Council of New Zealand; Health Research Council of New Zealand; U.S. Public Health Service, Grant/Award Numbers: R01 DA016558, R01-MH069864, R13-MH066849; John W. Alden Trust; Medical Research Council of South Africa (MRC); Robert Wood Johnson Foundation, Grant/Award Number: 044708; Pfizer Foundation

1 | INTRODUCTION

The World Mental Health (WMH) Survey Initiative of the World Health Organization (WHO) has significantly advanced our understanding of the global epidemiology of trauma and posttraumatic stress disorder (PTSD; Bromet, Karam, Koenen, & Stein, 2018). WMH data were collected from 26 countries using coordinated, rigorous, and innovative interviewing methods to comprise the largest cross-national data set on trauma and PTSD to date. The surveys have delineated rates of and risk factors for exposure to traumatic events (Benjet et al., 2016) and subsequent PTSD (Kessler et al., 2017), have clarified secondary psychiatric and medical morbidities (Kessler et al., 2011; Scott et al., 2016) as well as burden of disease (Kessler, Aguilar-Gaxiola, Alonso, Lee, & Koenen, 2018), and have provided data on health services use for PTSD in different contexts (Thornicroft et al., 2018). WMH data have also been used to address several clinical questions, such as optimal diagnostic criteria and identification of those at risk for PTSD (Karam et al., 2010; Stein et al., 2013, 2014).

Nevertheless, several epidemiological and clinical aspects of the treatment of PTSD deserve further attention. First, relatively little has been written about the perceived helpfulness of PTSD treatment (e.g., Cooper et al., 2017; Starzynski & Ullman, 2014). With increased focus on the lived experience of individuals suffering from mental disorders and on patient-centered care (Bellamy et al., 2016), this is a key gap. Second, there are few data on the longitudinal course of PTSD treatment, including data on perceived helpfulness over time, or data on persistence with treatment. Such data may be useful in informing clinical treatment guidelines, which are currently mainly based on randomized trials in highly controlled settings (explanatory designs) rather than on sequential investigations in everyday contexts (pragmatic designs; Fagioli et al., 2017; Janiaud, Dal-Re, & Ioannidis, 2018).

The probability of an individual with PTSD ever receiving helpful treatment is a joint function of the probability that any one treatment professional will be perceived as helpful and the probability that a patient will continue to seek treatment after an earlier treatment failure. Questions in the WMH surveys about perceived helpfulness of initial and subsequent treatments of PTSD, as well as on a range of variables previously found to predict treatment outcomes (e.g., trauma type, sociodemographics, prior mental disorder, and childhood adversities) provide a unique opportunity to examine

predictors of both these components. We aimed to address gaps in the literature on PTSD treatment by cross-national investigation of (a) the perceived helpfulness of initial and subsequent efforts to obtain treatment for PTSD and (b) the probability of persistence in help-seeking after initially obtaining unhelpful treatment, as the two main components in a patient eventually finding a treatment that they consider helpful.

2 | MATERIALS AND METHODS

2.1 | Samples

The WMH surveys are a coordinated set of community surveys administered to probability samples of the noninstitutionalized population in countries throughout the world (<https://www.hcp.med.harvard.edu/wmh/>; Kessler & Üstün, 2004). Data for the current report came from WMH surveys carried out in 18 surveys from 16 countries—10 in countries classified by the World Bank as high-income (Argentina, Australia, Israel, Japan, New Zealand, Northern Ireland, Portugal, Saudi Arabia, Spain, and United States) and six in countries classified as low- or middle-income (Brazil, Bulgaria, Colombia, Lebanon, Mexico, and Romania). There were two surveys in Bulgaria, administered to separate samples, and there are two surveys in Colombia (one national and one in Medellín). Eleven surveys were based on nationally representative household samples, whereas three were representative of selected Metropolitan Areas (Sao Paulo Brazil, Medellín Colombia, and Japan), one was representative of selected regions (Murcia Spain), and three were representative of all urbanized areas (Colombia, Mexico, and Argentina). Response rates ranged from 55.1% (Japan) to 97.2% (Medellin) and averaged 70.1% across surveys (see Table A1).

The interview schedule was developed in English and translated into other languages using a standardized WHO translation, back-translation, and harmonization protocol (Harkness et al., 2008). Interviews were administered face-to-face in respondents' homes after obtaining informed consent using procedures approved by local Institutional Review Boards. Study procedures were carried out in accordance with the latest version of the Declaration of Helsinki. Interviews were in two parts. Part I was administered to all respondents and assessed core *Diagnostic and Statistical Manual of Mental Disorders* (DSM-IV) mental disorders ($n = 88,444$ respondents across all surveys). Part II

assessed additional disorders and correlates and was administered to 100% of respondents who met lifetime criteria for any Part I disorder and a probability subsample of other Part I respondents ($n = 52,979$). Part II respondents were weighted to adjust for differential probabilities of selection into Part II and deviations between the sample and population demographic-geographic distributions. This weight resulted in prevalence estimates of Part I disorders in the weighted Part II sample being identical to those in the Part I sample (Heeringa et al., 2008).

2.2 | Measures

2.2.1 | Posttraumatic stress disorder

Diagnoses were based on Version 3.0 of the WHO's Composite International Diagnostic Interview (CIDI; Kessler & Üstün, 2004), a fully-structured lay-administered diagnostic interview. DSM-IV criteria were used to define PTSD along with a number of other anxiety disorders (generalized anxiety disorder, panic disorder, agoraphobia with or without panic disorder, specific phobia, and social phobia), mood disorders (major depressive disorder and bipolar disorder), and substance-use disorders (alcohol and drug abuse and dependence). The assessment of PTSD began with a series of questions about lifetime exposure to a wide range of traumatic experiences. When more than one lifetime traumatic experience was reported, PTSD was assessed twice: once for symptoms associated with the traumatic experience the respondent reported as having caused the most distress and impairment; and a second time for one randomly selected other traumatic experience. PTSD was assessed only once among respondents who reported having only one traumatic experience in their life and not at all among respondents who never had a traumatic experience. Item missing values on symptom reports were rare and were coded as if the symptom was absent when they occurred. Clinical reappraisal interviews were carried out in a number of WMH surveys using the lifetime nonpatient version of the Structured Clinical Interview for DSM-IV (SCID; First, Spitzer, Gibbon, & Williams, 2002) as the gold standard. Good agreement was found between diagnoses of PTSD based on the CIDI and on blinded SCID clinician-administered reappraisal interviews (area under the curve = 0.69, positive predictive value = .86; Haro et al., 2006).

2.2.2 | Helpful treatment

Respondents who met lifetime DSM-IV/CIDI criteria for PTSD were asked retrospectively about age-of-onset and were then asked whether they ever "talk(ed) to a medical doctor or other professional about" their PTSD and, if so, how old they were the first time they talked to a professional about their PTSD. "Other professionals" were defined broadly to include "psychologists, counselors, spiritual advisors, herbalists, acupuncturists, and other healing professionals." Respondents answering yes were then asked whether they ever got treatment for their PTSD "that you considered *helpful* or *effective* (*emphasis in original*). If so, they were

asked how many professionals they ever talked to about their PTSD "up to and including the first time you ever got helpful treatment." Respondents who said they never got helpful treatment, in comparison, were asked how many professionals they ever talked to about their PTSD. Only respondents who reported receiving treatment for their PTSD were included in the analyses. The few with item missing values on age of first treatment, age of first helpful treatment and number of professionals seen for each country were analyzed based on regression-based imputations of the missing items that took into account scores on the reported items as well as other patient reported characteristics.

2.2.3 | Predictors of helpful treatment

Socioeconomic characteristics included age at first PTSD treatment (continuous), sex, marital status (married, never married, previously married), and education (in quartiles defined by within-country distributions). Item missing values of demographic predictors were uncommon due to the fact that surveys were interviewer administered. The few missing items were imputed using regression-based imputation methods. Childhood adversities (CAs) occurring before age 18 years were assessed retrospectively. These included CAs related to family dysfunction (physical abuse, sexual abuse, neglect, parent mental disorder, parent substance use disorder, parent criminal behavior and family violence), and well as others (parent died, parent divorced, other parent loss, physical illness, and economic adversity). Lifetime comorbid conditions included number of anxiety, mood, and substance use disorders with first onsets before the age the respondent first sought treatment. Item missing values on childhood adversities and comorbid symptoms were rare and were coded as if absent when they occurred. Treatment type was defined as the cross-classification of variables for (a) whether the respondent reported receiving medication, talk therapy, or both, as of the age of first PTSD treatment; and (b) types of treatment providers seen as of that age, including mental health specialists (psychiatrist, psychiatric nurse, psychologist, psychiatric social worker, mental health counselor) with or without pharmacotherapy, primary care providers, human services providers (social worker or counselor in a social services agency, spiritual advisor), and complementary/alternative medicine (other type of healer or self-help group). Treatment timing included a dichotomous measure for whether the respondent's first attempt to seek treatment occurred before 2000 or subsequently and a continuous variable for length of delay in years between age-of-onset of PTSD and age of initially seeking treatment. The year 2000 corresponds to the midpoint when treatment was first received by patients in the sample and also aligns with the first FDA approval (December 1999) for an evidence-based treatment of PTSD. Item missing values were uncommon and were imputed using regression-based imputation methods.

2.3 | Analysis methods

The sample for analysis was limited to people with onset of lifetime DSM-IV PTSD treatment on or after 1990 in order to minimize potential

effects of recall bias. The probability of obtaining helpful treatment is a joint function of the probability that any one treatment provider will be perceived as helpful and the probability that a patient will continue to seek treatment after an initial treatment encounter considered to be unhelpful. To investigate these two components separately, we used discrete-event survival analysis to calculate the conditional and cumulative probabilities of (a) obtaining helpful treatment after seeing between one and six professionals; and (b) persisting in seeking treatment from up to six professionals after failing to obtain helpful treatment from the previous professional(s) seen (Halli & Rao, 1992). We followed patients up through six professionals, because this was the last number where at least 30 patients received treatment. We then carried out parallel discrete-event survival analyses of the predictors of these two component outcomes using standard discrete-time methods and a logistic link function (Willett & Singer, 1993). Because the WMH sample designs used weighting and clustering, all statistical analyses were carried out using the Taylor series linearization method (Volter, 1985), a design-based method implemented in the SAS 9.4 program (SAS Institute Inc., 2016). Logistic regression coefficients and ± 2 of their design-based standard errors were exponentiated to create odds ratios (ORs) and 95% confidence intervals (CIs). Significance tests of sets of coefficients were made using Wald χ^2 tests based on design-corrected coefficient variance-covariance matrices. Statistical significance was evaluated consistently using two-sided design-based .05 level tests.

3 | RESULTS

3.1 | PTSD prevalence and treatment

Lifetime prevalence of PTSD was 5.3% in high-income countries, 2.3% in low/middle-income countries, and 4.4% in the total sample (Table 1). Among respondents with lifetime PTSD, 26.4% in high-income countries ever sought treatment compared to 6.8% in low/middle-income countries and 23.5% in the total sample. Roughly half these patients (57.0%) reported that treatment was helpful. This proportion did not differ significantly between high- and low/middle-income countries (57.6% vs. 43.8%, $\chi^2_1 = 2.1$; $p = .15$). Median of providers seen was higher for patients who obtained helpful treatment than not in high-income countries (1.3 vs. 1.0) but not low/middle-income countries (1.0 vs. 1.0).

3.2 | Helpful PTSD treatment across professionals seen

Probability of obtaining helpful PTSD treatment from the first professional seen was 24.0% in the total sample (Table 2). Conditional probabilities of subsequent professionals being helpful if they were seen after earlier unhelpful treatments were in the range of 22.7 to 32.7% and did not vary significantly depending on number of prior unhelpful treatments ($\chi^2_4 = 1.98$; $p = .74$). These proportions were very similar in high-income versus low/middle-income countries.

Survival analysis based on these conditional probabilities suggests that the cumulative probability of receiving helpful treatment from at least one treatment provider would increase from 24.0% after the first professional seen to 48.8% if all patients continued to a second provider after a first treatment failure. This estimated cumulative probability would increase to an estimated 85.7% if all patients persevered in trying up to six professionals after earlier ones were unhelpful. These patterns were generally similar across country income levels (see also Table A2 for the probabilities up to the 49th professional).

3.3 | Persistence with PTSD treatment seeking following earlier unhelpful treatment

In the total sample, 67.9% of patients who were not helped by the first professional seen persisted in seeing a second professional (Table 3; see also Table A3 for the probabilities up to the 49th professional). Further persistence after unhelpful treatments from between one and four subsequent professionals was in the range 65.6 to 92.5% and varied significantly depending on number of prior unhelpful treatments ($\chi^2_3 = 17.4$; $p \leq .001$). These proportions were very similar in high-income versus low/middle-income countries.

However, not all patients persisted after each unhelpful attempt. Survival analysis based on the conditional probabilities suggests that the cumulative probability of persisting with up to six professionals in the face of prior treatments being unhelpful would be 23.6% in the total sample. Again, patterns were generally similar across country income levels.

3.4 | Predictors of helpful PTSD treatment

We noted above that 57.0% of the patients who sought treatment for their PTSD reported that they received helpful treatment. Logistic regression analysis at the person-level (i.e., ignoring the number of treatment providers consulted) pooled across this entire sample adjusting for between-country differences found that odds of obtaining helpful treatment was not significantly related to any of the socio-demographic variables considered (age at first PTSD treatment, sex, marital status at the time of initiating treatment, education level at the time of initiating treatment) or to the type of traumatic experience that caused the PTSD (Table 4). However, five other predictors were significant. Length of delay in seeking treatment after onset of PTSD was inversely related to odds of treatment being helpful. Patients who first obtained treatment in 2000 or later were significantly less likely than those whose treatment began in earlier years to report obtaining helpful treatment. Treatment type was important: the highest odds of helpful treatment was associated with receiving psychotropic medication from a specialty mental health provider and the lowest with treatment in the complementary/alternative medicine sector. Comorbid anxiety disorders were important, although this association was due to patients with exactly 2 but not 3+ other prior anxiety disorders being associated with low

TABLE 1 Lifetime prevalence of DSM-IV posttraumatic stress disorder, proportion of cases with lifetime PTSD who obtained treatment, and proportion of treated cases who perceived treatment as helpful

	In the entire sample				Among respondents with lifetime PTSD				Among cases that obtained lifetime PTSD treatment ^a				
	Prevalence of PTSD		Percentage obtained treatment ^a		Percentage perceived treatment as helpful ^b		Number of professionals seen by those who received treatment they never considered helpful ^b		Number of professionals seen by those who received treatment they considered helpful ^b				
	(n)	%	(SE)	(n)	%	(SE)	(n)	%	(SE)	Median	(IQR)	Median	(IQR)
I. Low/middle-income countries													
Low/middle-income countries	(15,557)	2.3	(0.1)	(605)	6.8	(1.2)	(53)	43.8	(9.2)	1.0	(1.0–2.4)	1.0	(1.0–1.6)
Colombia	(2,381)	1.8	(0.4)	(58)	4.1	(3.1)	(2)	0.0	(0.0)	1.0	(1.0–1.0)	–	
Sao Paulo, Brazil	(2,942)	3.2	(0.2)	(160)	8.3	(3.0)	(17)	27.5	(14.4)	2.3	(1.0–2.7)	1.0	(1.0–1.3)
Bulgaria	(2,811)	2.0	(0.3)	(109)	10.3	(2.8)	(14)	71.1	(15.7)	1.5	(1.1–1.9)	1.0	(1.0–2.1)
Lebanon	(1,031)	3.4	(0.6)	(70)	2.5	(1.8)	(2)	100.0	(0.0)	–		1.0	(1.0–1.4)
Medellin, Colombia	(1,673)	3.7	(0.6)	(109)	7.5	(2.6)	(12)	36.6	(16.0)	1.0	(1.0–1.1)	1.0	(1.0–45.1)
Mexico	(2,362)	1.5	(0.3)	(68)	3.1	(1.8)	(4)	32.0	(22.9)	1.0	(1.0–1.0)	1.0	(1.0–1.0)
Romania	(2,357)	1.2	(0.3)	(31)	6.9	(5.2)	(2)	65.8	(31.8)	1.0	(1.0–1.0)	1.0	(1.0–1.0)
χ^2	41.9*			6.9			1100.6*						
II. High-income countries													
High-income countries	(37,422)	5.3	(0.1)	(2,906)	26.4	(1.1)	(726)	57.6	(2.4)	1.0	(1.0–1.7)	1.3	(1.0–2.3)
Argentina	(2,116)	2.8	(0.3)	(122)	19.9	(3.7)	(26)	75.4	(10.9)	1.0	(1.0–1.0)	1.0	(1.0–1.6)
Australia	(8,463)	7.3	(0.4)	(640)	39.8	(2.6)	(253)	68.4	(3.7)	1.1	(1.0–1.8)	1.3	(1.0–2.3)
Israel	(4,859)	1.6	(0.2)	(73)	12.0	(4.1)	(8)	47.3	(18.3)	1.0	(1.0–1.4)	1.0	(1.0–1.5)
Japan	(1,682)	1.3	(0.2)	(38)	16.7	(7.5)	(4)	67.4	(26.0)	3.0	(3.0–3.0)	1.0	(1.0–1.0)
Murcia, Spain	(1,459)	2.8	(0.5)	(65)	19.1	(3.7)	(16)	84.9	(11.5)	1.0	(1.0–1.0)	1.0	(1.0–1.4)
New Zealand	(7,312)	6.1	(0.3)	(828)	19.1	(2.0)	(168)	40.2	(5.7)	1.0	(1.0–1.4)	1.5	(1.0–2.7)
Northern Ireland	(1,986)	8.8	(0.7)	(238)	39.2	(4.3)	(80)	53.5	(7.1)	1.0	(1.0–1.6)	1.7	(1.0–2.5)
Portugal	(2,060)	5.3	(0.5)	(180)	28.7	(4.4)	(64)	45.2	(6.9)	1.0	(1.0–1.7)	1.2	(1.0–1.8)
United States	(5,692)	6.9	(0.4)	(602)	16.0	(1.5)	(104)	42.3	(4.2)	1.1	(1.0–1.9)	1.4	(1.0–2.4)
Saudi Arabia	(1,793)	3.6	(0.5)	(120)	2.4	(1.8)	(3)	100.0	(0.0)	–		1.5	(1.2–1.9)
χ^2	321.6*			106.6*			321.0*						
III. Pooled countries													
All countries	(52,979)	4.4	(0.1)	(3,511)	23.5	(1.0)	(779)	57.0	(2.4)	1.0	(1.0–1.8)	1.3	(1.0–2.2)
χ^2_{16}	537.1*			174.4*			1130.1*						
Low/middle-income countries vs. High-income countries	181.4*			64.4*			2.1						
χ^2_1													

Abbreviations: IQR, interquartile range; SE, standard error.

^aCases are based on three conditions: (a) Respondents obtained PTSD treatment; (b) year of first PTSD treatment was 1990 or later; and (c) age at onset of PTSD was the year of first PTSD treatment or earlier.^bCases are based on four conditions: (a) Respondents obtained PTSD treatment; (b) year of first PTSD treatment was 1990 or later; (c) age at onset of PTSD was the year of first PTSD treatment or earlier; and (d) respondents obtained helpful treatment.

*Significant at the .05 level, two-sided test.

odds of PTSD treatment being helpful. And patients with a history of childhood adversity were less likely to obtain helpful treatment. Exclusion of nonsignificant predictors did not modify the strength of the significant predictors meaningfully (Table A4).

Decomposition of probabilities (i.e., of getting helpful treatment and of persistence in help-seeking after initially obtaining unhelpful treatment) showed that the pathways accounting for these significant associations varied considerably. Delay in seeking treatment, historical time (treated in 2000 or later), and childhood adversities were all inversely related to persistence, but were not significantly associated with a particular treatment provider being perceived as helpful. Prior comorbid anxiety disorders, however, were inversely related to perceiving treatment as helpful, but were not related to persistence after unhelpful treatment. Finally, seeking help from a mental health specialist who provided psychotherapy was significantly associated with perceiving treatment as helpful but not with persisting after unhelpful treatment, whereas seeing a mental health specialist who prescribed medication was a significant predictor of persistence but not helpfulness.

We carried out additional analyses to determine whether these significant predictors varied in importance between high- and low/middle-income countries. None of these differences was statistically significant, although it needs to be noted that the number of patients in low/middle-income countries was too small for statistically powerful analyses of these interactions. We also investigated the possibility of time trends in the significant associations; only one emerged as significant at the .05 level: a stronger association between childhood adversities and decreased odds of treatment being helpful since 2000 than before (see Table A5).

4 | DISCUSSION AND CONCLUSION

Several limitations of this study deserve emphasis. One of these is that assessment of key PTSD treatment and treatment response features was based on sparse information. Respondent judgments of the helpfulness of PTSD treatment were based on a single question, which might be understood differently by different respondents. Responses were uncorroborated, uncontrolled, and retrospective. More in-depth and formal measures of patient perceptions of care are available (Oades, Law, & Marshall, 2011; Uttaro, 2003). And controlled trials are needed to determine helpfulness in an objective fashion (i.e., efficacy and effectiveness of care using validated outcome measures). Telescoping (dating past events as occurring more recently than they did) might have led to inaccuracy in estimates of the timing of treatment (Barsky, 2002), although we restricted the sample to patients with onset of PTSD treatment no earlier than 1990 to help address the limitations of recall. In addition, assessment of the precise nature of PTSD treatment was limited to a small number of superficial questions, such as whether and when respondents “talk(ed) to a professional about their PTSD,” so questions about how evidence-based the interventions were, cannot be

addressed. Finally, assessment of PTSD symptoms, as well as of other key clinical features, at the time of treatment was not undertaken.

While the above paragraph makes it clear that the findings reported here are quite different in scope from those obtained in randomized controlled trials (RCTs) of PTSD interventions, they are important precisely because they address questions which that literature cannot. To our knowledge, this is the first cross-national epidemiological study of perceived helpfulness of PTSD treatment. It is encouraging that we find a slight majority (57.0%) of patients with lifetime PTSD across the world saying that they found their treatment to be helpful. But we estimated that the vast majority (85.7%) might have experienced helpful treatment if they had persevered in trying up to six professionals after earlier treatment failures. However, only a minority of patients persisted in their help-seeking to that extent.

The first of these results is consistent with RCTs of PTSD treatment, which demonstrate that treatment nonresponse rates are comparatively high and treatment effect sizes are comparatively low even though a number of PTSD interventions are efficacious (Charney, Hellberg, Bui, & Simon, 2018; Difede, Olden, & Cukor, 2014). However, we are unaware of previous research that has investigated the issue of persistence in help-seeking. It is encouraging that across all countries, 67.9% of patients who were not helped by the first professional seen persisted in seeing at least one additional professional. Still, not all people persisted after each unhelpful attempt and we estimated that the cumulative probability of persisting with up to six professionals was only 23.6%.

Our projected estimate that the great majority of patients would have been helped if they had persisted in help-seeking is based on the implicit assumption that people who did not persist with treatment would have had comparable outcomes to those who did if they had persisted. But this is far from certain, as unmeasured variables associated with low persistence (e.g., particular personality traits) might also influence the perception of treatment being unhelpful, in which case efforts to encourage greater persistence in help-seeking would not lead to the good outcomes suggested here. However, the fact that conditional probabilities of treatment being perceived as helpful remained fairly stable regardless of number of prior treatment failures is striking and supports the argument that clinical treatment guidelines for PTSD should encourage patients to persist in help-seeking even after they found a number of treatments not to be helpful. Similarly, conceptual frameworks to enhance person-centered PTSD care should be expanded to include factors addressing treatment motivations and expectations (Etingen et al., 2019; Sharma, Bamford, & Dodman, 2015).

The data reported here on the predictors of perceived helpfulness are also of interest in delineating the pathways that account for the helpfulness of individual clinical encounters and persistence in seeking help after initial unhelpful encounters. Receiving treatment from a mental health specialist who employed psychotherapy was a significant predictor of PTSD treatment being perceived as helpful, but not of persistence with help-seeking after unhelpful treatment. In contrast, shorter delay to treatment, earlier historical time, and receiving treatment from a mental health specialist who prescribed

TABLE 2 Conditional and cumulative probabilities of PTSD treatment being perceived as helpful after each professional seen, among respondents with lifetime DSM-IV PTSD who obtained treatment

	I. Conditional probabilities									II. Cumulative probabilities					
	All			High-income countries			Low/middle-income countries			All (n = 779)		High-income countries (n = 726)		Low/middle-income countries (n = 53)	
	%	(SE)	(n)	%	(SE)	(n)	%	(SE)	(n)	%	(SE)	%	(SE)	%	(SE)
Number of professionals seen after which treatment was perceived as helpful															
1	24.0	(2.3)	(779)	23.8	(2.4)	(726)	27.7	(2.4)	(53)	24.0	(2.3)	23.8	(2.4)	27.7	(2.4)
2	32.7	(2.8)	(417)	33.2	(2.9)	(395)	19.4	(6.0)	(22)	48.8	(2.8)	49.1	(2.9)	41.7	(10.2)
3	31.4	(3.7)	(198)	32.5	(3.9)	(183)	12.0	(1.1)	(15)	64.9	(2.9)	65.6	(3.0)	48.7	(10.9)
4	30.1	(7.9)	(97)	30.4	(8.1)	(93)	21.0	(16.6)	(4)	75.5	(2.9)	76.1	(2.9)	59.5	(15.2)
5	22.7	(5.8)	(57)	23.2	(6.0)	(55)	0.0	(0.0)	(2)	81.1	(2.8)	81.6	(2.7)	59.5	(15.2)
6	24.8	(7.0)	(40)	25.5	(7.2)	(38)	0.0	(0.0)	(2)	85.7	(2.6)	86.3	(2.6)	59.5	(15.2)

Abbreviations: PTSD, posttraumatic stress disorder; SE, standard error.

TABLE 3 Conditional and cumulative probability of persistence with treatment after previous unhelpful attempts, among respondents with lifetime DSM-IV PTSD who obtained treatment

	I. Conditional probabilities									II. Cumulative probabilities					
	All			High-income countries			Low/middle-income countries			All (n = 616)		High-income countries (n = 580)		Low/middle-income countries (n = 36)	
	%	(SE)	(n)	%	(SE)	(n)	%	(SE)	(n)	%	(SE)	%	(SE)	%	(SE)
Number of professionals seen if not helped by the previous one															
2	67.9	(2.0)	(616)	68.3	(2.1)	(580)	58.0	(2.6)	(36)	67.9	(2.0)	68.3	(2.1)	58.0	(2.6)
3	70.6	(3.0)	(281)	70.0	(3.1)	(263)	84.1	(3.1)	(18)	48.0	(3.0)	47.9	(3.1)	48.8	(11.0)
4	65.6	(3.5)	(145)	68.2	(3.6)	(132)	27.3	(4.2)	(13)	31.5	(3.0)	32.7	(3.1)	13.3	(6.9)
5	81.1	(4.4)	(73)	81.8	(4.6)	(70)	57.9	(0.0)	(3)	25.5	(3.0)	26.7	(3.2)	7.7	(5.4)
6	92.5	(5.1)	(43)	92.2	(5.2)	(41)	100.0	(0.0)	(2)	23.6	(3.1)	24.7	(3.3)	7.7	(5.4)

Abbreviations: PTSD, posttraumatic stress disorder; SE, standard error.

medication were not associated with a particular treatment being considered helpful but nonetheless predicted increased probability of the patient eventually receiving helpful treatment because these variables predicted persistence after earlier unhelpful treatments. Childhood adversities were inversely related to persistence after unhelpful treatment, and comorbid anxiety disorders were associated with perceiving treatment as unhelpful.

These findings are partially consistent with clinical studies of treatment response in PTSD, some of which have found a relationship between childhood adversity and worse outcome (Marshall et al., 1998), and they support PTSD treatment guidelines which emphasize the importance of addressing comorbid conditions (Najavits et al., 2009). However, they also provide novel findings, such as those regarding delayed initiation of help-seeking, and generate hypotheses about mechanisms that deserve further investigation as potential intervention targets. The finding that those with more delayed treatment and those who received treatment since 2000 were less likely to persist with treatment suggests that

additional efforts may need to be devoted to psychoeducation emphasizing that best PTSD treatment should be initiated early and that the best PTSD treatment still requires a trial-and-error approach and great persistence.

We are mindful of the key point that professionals and treatments for PTSD and other disorders are not simply interchangeable (Maj, 2020). It is notable that psychotherapy provided by a mental health specialist predicted early helpfulness, while pharmacotherapy provided by a mental health specialist predicted persistence and so eventual helpfulness. While it is possible that persisting with treatment is associated with more severe symptoms (e.g., those thought by the clinical to require medication), our findings can also be read as supporting the point that evidence-based interventions by suitably qualified clinicians, provided within the context of a strong therapeutic alliance and shared decision-making, are important for improving outcomes. Certainly, increased treatment rates, in the absence of efficacious treatments and increased persistence rates, will not decrease prevalence optimally.

TABLE 4 Predictors of helpful treatment and persistence (pooled across professionals seen), and predictors of perceived helpfulness of treatment (person level), among people with lifetime DSM-IV PTSD who obtained treatment

	Model 1: Predicting helpful treatment pooled across professionals seen				Model 2: Predicting persistence pooled across treatment failure				Model 3: Predicting perceived helpfulness of treatment across PTSD patients			
	Prevalence		Multivariate		Prevalence		Multivariate		Prevalence		Multivariate	
	Mean/%	(SE)	AOR	(95% CI)	Mean/%	(SE)	AOR	(95% CI)	Mean/%	(SE)	AOR	(95% CI)
Age at first posttraumatic stress treatment	35.0	(0.7)	1.01	(0.99–1.02)	35.2	(0.8)	1.00	(0.99–1.01)	35.5	(0.6)	1.00	(0.99–1.02)
χ^2_1			1.18				0.00				0.06	
Female	69.1	(2.6)	1.03	(0.72–1.46)	68.7	(2.7)	0.93	(0.62–1.40)	69.1	(2.5)	1.31	(0.77–2.24)
Male	30.9	(2.6)	1.00	–	31.3	(2.7)	1.00	–	30.9	(2.5)	1.00	–
χ^2_1			0.02				0.11				0.98	
Marital status												
Never married	41.8	(2.4)	1.39	(0.97–1.99)	41.3	(2.6)	0.91	(0.58–1.44)	41.9	(2.0)	0.92	(0.53–1.58)
Previously married	29.0	(2.8)	1.20	(0.79–1.81)	29.3	(3.0)	1.04	(0.65–1.66)	29.1	(2.1)	1.13	(0.66–1.92)
Currently married	29.2	(2.3)	1.00	–	29.4	(2.6)	1.00	–	29.0	(1.9)	1.00	–
χ^2_2			3.50				0.27				0.42	
Education												
Low	8.2	(1.1)	0.72	(0.43–1.21)	8.9	(1.2)	0.74	(0.39–1.39)	9.4	(1.0)	0.50*	(0.26–0.96)
Low-average	24.8	(2.6)	0.93	(0.61–1.42)	24.0	(2.7)	1.13	(0.71–1.80)	25.6	(2.1)	0.92	(0.55–1.56)
High-average	33.9	(2.2)	0.81	(0.55–1.20)	34.9	(2.5)	0.84	(0.56–1.26)	33.2	(2.1)	0.60*	(0.38–0.93)
High	21.2	(2.3)	1.00	–	20.7	(2.5)	1.00	–	20.7	(1.9)	1.00	–
Student	11.9	(1.6)	0.82	(0.48–1.40)	11.6	(1.8)	1.13	(0.54–2.38)	11.1	(1.3)	0.90	(0.39–2.06)
χ^2_4			2.38				3.01				8.67	
Treatment delay (years) ^a	9.2	(0.7)	0.99	(0.97–1.00)	9.6	(0.8)	0.98*	(0.97–0.99)	9.7	(0.6)	0.98*	(0.96–0.99)
χ^2_1			3.75				7.70*				6.56*	
Started PTSD treatment \geq 2000 (vs. 1990–1999)	57.2	(2.4)	0.82	(0.61–1.10)	57.5	(2.7)	0.50*	(0.34–0.74)	62.6	(2.0)	0.45*	(0.29–0.69)
χ^2_1			1.74				11.77*				13.20*	
Treatment type ^b												
Mental health specialist + Psychotherapy	51.9	(2.5)	1.51*	(1.02–2.23)	52.5	(2.7)	1.59	(0.95–2.68)	51.0	(2.2)	2.01*	(1.19–3.40)
Mental health specialist + Medication	68.1	(2.3)	1.42	(0.91–2.21)	68.3	(2.5)	1.88*	(1.29–2.73)	60.2	(2.4)	2.18*	(1.31–3.60)
General medical	80.8	(1.6)	0.77	(0.55–1.09)	82.0	(1.6)	1.61*	(1.01–2.57)	76.3	(1.8)	1.06	(0.63–1.78)
Complementary/alternative medicine	26.6	(2.0)	1.07	(0.75–1.51)	27.5	(2.2)	0.79	(0.54–1.14)	24.5	(2.0)	0.90	(0.55–1.47)

(Continues)

TABLE 4 (Continued)

	Model 1: Predicting helpful treatment pooled across professionals seen				Model 2: Predicting persistence pooled across treatment failure				Model 3: Predicting perceived helpfulness of treatment across PTSD patients			
	Prevalence		Multivariate		Prevalence		Multivariate		Prevalence		Multivariate	
	Mean/%	(SE)	AOR	(95% CI)	Mean/%	(SE)	AOR	(95% CI)	Mean/%	(SE)	AOR	(95% CI)
Human services χ^2_{4}	24.9	(2.4)	1.00	-	26.5	(2.7)	1.00	-	22.9	(2.1)	1.00	-
			11.80*				17.90*				13.68*	
Exactly 2 or more of the above χ^2_{1} χ^2_{5}	79.6	(1.7)	0.55	(0.30-1.00)	80.5	(1.8)	1.39	(0.78-2.48)	72.2	(2.0)	0.89	(0.46-1.72)
			3.79				1.22				0.13	
			13.14*				37.51*				22.98*	
Number of lifetime anxiety disorders ^c												
3 or more lifetime anxiety disorders ^c	34.4	(2.4)	0.87	(0.62-1.21)	35.9	(2.6)	1.43	(0.95-2.14)	28.3	(1.9)	1.33	(0.85-2.06)
Exactly 2 lifetime anxiety disorders ^c	28.4	(2.2)	0.68*	(0.47-0.98)	29.3	(2.5)	0.77	(0.52-1.15)	30.7	(2.1)	0.53*	(0.34-0.84)
Exactly 1 lifetime anxiety disorder ^c	37.2	(2.5)	1.00	-	34.8	(2.7)	1.00	-	40.9	(2.3)	1.00	-
χ^2_{2}			5.16				10.92*				18.35*	
Lifetime mood disorders												
Major depressive disorder	48.9	(2.6)	1.06	(0.80-1.41)	49.2	(2.9)	1.12	(0.76-1.66)	46.2	(2.0)	1.11	(0.73-1.69)
Bipolar disorder	11.9	(1.6)	1.22	(0.70-2.14)	12.5	(1.8)	0.80	(0.47-1.35)	11.5	(1.4)	0.84	(0.43-1.62)
χ^2_{2}			0.52				2.04				0.83	
Lifetime substance use disorders												
Alcohol and/or drug abuse	35.4	(2.6)	0.90	(0.67-1.21)	36.4	(2.7)	1.26	(0.88-1.81)	31.2	(2.4)	1.13	(0.74-1.72)
Alcohol or drug dependence but not abuse	2.2	(0.5)	1.74	(0.66-4.61)	2.1	(0.5)	1.15	(0.65-2.04)	2.6	(0.6)	1.43	(0.51-4.00)
χ^2_{2}			1.81				1.57				0.67	
χ^2_{6}			8.24				14.43*				22.13*	
Traumatic events implicated in the PTSD												
Exposure to organized violence ^d	15.8	(1.9)	0.64*	(0.42-0.98)	16.9	(2.0)	1.21	(0.78-1.87)	14.3	(1.5)	0.78	(0.42-1.42)
Participation in organized violence ^e	44.0	(2.6)	1.13	(0.87-1.47)	44.7	(2.8)	1.03	(0.72-1.46)	41.9	(2.3)	1.10	(0.73-1.64)

TABLE 4 (Continued)

	Model 1: Predicting helpful treatment pooled across professionals seen			Model 2: Predicting persistence pooled across treatment failure			Model 3: Predicting perceived helpfulness of treatment across PTSD patients		
	Prevalence	Multivariate	Prevalence	Multivariate	Prevalence	Multivariate	Prevalence	Multivariate	
	Mean/% (SE)	AOR (95% CI)	Mean/% (SE)	AOR (95% CI)	Mean/% (SE)	AOR (95% CI)	Mean/% (SE)	AOR (95% CI)	
Physical violence victimization ^f	33.7 (2.4)	0.59* (0.43–0.80)	35.7 (2.6)	1.48 (0.99–2.21)	27.4 (2.2)	0.79 (0.48–1.31)			
Sexual violence victimization ^g	63.7 (2.2)	1.31 (0.97–1.77)	63.1 (2.4)	1.05 (0.74–1.49)	63.0 (2.1)	1.34 (0.91–1.98)			
Accidents/injuries ^h	51.3 (2.7)	0.97 (0.97–1.40)	53.1 (3.0)	1.21 (0.84–1.76)	48.7 (2.0)	1.03 (0.68–1.58)			
Other ⁱ	66.7 (2.5)	0.95 (0.71–1.26)	67.7 (2.7)	0.97 (0.66–1.42)	64.5 (2.2)	0.98 (0.63–1.52)			
χ^2_6	22.61*		7.80		3.49				
Childhood adversities									
Family dysfunction ^l	30.8 (1.7)	0.79 (0.57–1.10)	34.0 (2.0)	0.88 (0.62–1.25)	29.6 (1.5)	0.71 (0.47–1.08)			
Other ^k	12.9 (1.1)	0.75 (0.54–1.05)	14.3 (1.2)	0.51* (0.37–0.70)	16.0 (1.2)	0.40* (0.26–0.60)			
χ^2_2	5.07		18.93*		21.84*				
Global χ^2_{29}	86.82*		194.32*		100.70*				

Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; PTSD, posttraumatic stress disorder; SE, standard error.

^aTreatment delay (years) = Age at first PTSD treatment – Age at onset of PTSD.

^bTreatment providers: mental health specialists (psychiatrist, psychiatric nurse, psychologist, psychiatric social worker, mental health counselor), primary care providers, human services providers (social worker or counselor in a social services agency, spiritual advisor), and complementary/alternative medicine (other type of healer or self-help group).

^cLifetime anxiety disorders include generalized anxiety disorder, panic disorder, agoraphobia with or without panic disorder, posttraumatic stress disorder, specific phobia and social phobia.

^dExposure to organized violence includes relief worker in war zone, civilian in war zone, civilian in region of terror, refugee and kidnapped.

^eParticipation in organized violence includes witnessed death/dead body/serious injury, accidentally caused serious injury/death, combat experience, purposely injured/tortured/killed someone and witnessed atrocities.

^fPhysical violence victimization includes beaten by caregiver, beaten by someone else and witnessed physical fight at home.

^gSexual violence victimization includes raped, sexually assaulted, stalked, beaten by spouse/romantic partner, trauma to loved one, some other trauma and private trauma.

^hAccidents/injuries includes natural disaster, toxic chemical exposure, automobile accident, life-threatening illness, child with serious illness and other life-threatening accident.

ⁱOther includes mugged/threatened with a weapon, human-made disaster and unexpected death of a loved one.

^jFamily dysfunction includes physical abuse, sexual abuse, neglect, parent mental disorder, parent substance use disorder, parent criminal behavior and family violence. Percentages represent the proportions of respondents with one or more of these childhood adversities.

^kOther childhood adversities include parent died, parent divorced, other parent loss, physical illness and economic adversity. Percentages represent the proportions of respondents with one or more of these childhood adversities.

*Significant at the .05 level, two-sided test

The findings here are relevant to a number of currently topical discussions in global health, including those on the scale-up of efficacious treatment (Patel et al., 2018) and those on precision medicine (Seymour et al., 2017). Given the treatment gap for common mental disorders such as PTSD, global mental health implementation science has investigated how best to scale-up efficacious interventions such as those outlined in mhGAP (World Health Organization, 2020). It is crucial that interventions are acceptable and accessible and that quality controls ensure fidelity (Stein, Bass, & Hofmann, 2019). Advances in data science have suggested that techniques such as machine learning may be useful in advancing precision psychiatry for a range of disorders, including PTSD; this may allow clinicians to reduce the extent to which treatment approaches rely on trial-and-error, and to develop more individually targeted treatment strategies (Kessler, Bossarte, Luedtke, Zaslavsky, & Zubizarreta, 2019). Measurement-based care and shared decision-making may also enhance patient-centered care of common mental disorders, including PTSD (Fortney et al., 2017).

In summary, these data on PTSD treatment from the WMH Survey Initiative are encouraging in emphasizing how often treatment of PTSD is perceived as helpful in the community, but they also suggest the need for more effective PTSD interventions. From a public health perspective, the findings here are consistent with calls for both scale-up of efficacious interventions for common mental disorders, as well as with calls for improved treatment targeting in mental health practice. The estimation that across the world, with persistence in treatment, the vast majority of people with PTSD may eventually perceive treatment as helpful, is a novel one and may usefully inform current treatment guidelines. Further work is needed to determine the extent to which targeted interventions to improve PTSD treatment quality and persistence will improve outcomes.

ACKNOWLEDGMENTS

The World Health Organization World Mental Health (WMH) Survey Initiative is supported by the United States National Institute of Mental Health (NIMH; R01 MH070884), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the United States Public Health Service (R13-MH066849, R01-MH069864, and R01 DA016558), the Fogarty International Center (FIRCA R03-TW006481), the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical Inc., GlaxoSmithKline, and Bristol-Myers Squibb. The authors thank the staff of the WMH Data Collection and Data Analysis Coordination Centres for assistance with instrumentation, fieldwork, and consultation on data analysis. None of the funders had any role in the design, analysis, interpretation of results, or preparation of this paper. The views and opinions expressed in this report are those of the authors and should not be construed to represent the views of the World Health Organization, other sponsoring organizations, agencies, or governments.

A complete list of all within-country and cross-national WMH publications can be found at <http://www.hcp.med.harvard.edu/wmh/>

The Argentina survey—Estudio Argentino de Epidemiología en Salud Mental (EASM)—was supported by a grant from the Argentinian Ministry

of Health (Ministerio de Salud de la Nación) – (Grant Number 2002–17270/13–5). The 2007 Australian National Survey of Mental Health and Wellbeing is funded by the Australian Government Department of Health and Ageing. The São Paulo Megacity Mental Health Survey is supported by the State of São Paulo Research Foundation (FAPESP) Thematic Project Grant 03/00204-3. The Bulgarian Epidemiological Study of common mental disorders EPIBUL is supported by the Ministry of Health and the National Center for Public Health Protection. EPIBUL 2, conducted in 2016–17, is supported by the Ministry of Health and European Economic Area Grants. The Colombian National Study of Mental Health (NSMH) is supported by the Ministry of Social Protection. The Mental Health Study Medellín – Colombia was carried out and supported jointly by the Center for Excellence on Research in Mental Health (CES University) and the Secretary of Health of Medellín. The Israel National Health Survey is funded by the Ministry of Health with support from the Israel National Institute for Health Policy and Health Services Research and the National Insurance Institute of Israel. The World Mental Health Japan (WMHJ) Survey is supported by the Grant for Research on Psychiatric and Neurological Diseases and Mental Health (H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013, H25-SEISHIN-IPPAN-006) from the Japan Ministry of Health, Labour and Welfare. The Lebanese Evaluation of the Burden of Ailments and Needs Of the Nation (L.E.B.A.N.O.N.) is supported by the Lebanese Ministry of Public Health, the WHO (Lebanon), National Institute of Health/Fogarty International Center (R03 TW006481-01), anonymous private donations to IDRAAC, Lebanon, and unrestricted grants from, Algorithm, AstraZeneca, Benta, Bella Pharma, Eli Lilly, Glaxo Smith Kline, Lundbeck, Novartis, OmniPharma, Pfizer, Phenicia, Servier, UPO. The Mexican National Comorbidity Survey (MNCS) is supported by The National Institute of Psychiatry Ramon de la Fuente (INPRFMDIES 4280) and by the National Council on Science and Technology (CONACyT-G30544- H), with supplemental support from the Pan American Health Organization (PAHO). Te Rau Hinengaro: The New Zealand Mental Health Survey (NZMHS) is supported by the New Zealand Ministry of Health, Alcohol Advisory Council, and the Health Research Council. The Nigerian Survey of Mental Health and Wellbeing (NSMHW) is supported by the WHO (Geneva), the WHO (Nigeria), and the Federal Ministry of Health, Abuja, Nigeria. The Northern Ireland Study of Mental Health was funded by the Health & Social Care Research & Development Division of the Public Health Agency. The Portuguese Mental Health Study was carried out by the Department of Mental Health, Faculty of Medical Sciences, NOVA University of Lisbon, with collaboration of the Portuguese Catholic University, and was funded by Champalimaud Foundation, Gulbenkian Foundation, Foundation for Science and Technology (FCT) and Ministry of Health. The Romania WMH study projects "Policies in Mental Health Area" and "National Study regarding Mental Health and Services Use" were carried out by National School of Public Health & Health Services Management (former National Institute for Research & Development in Health), with technical support of Metro Media Transilvania, the National Institute of Statistics-National Centre for Training in Statistics, SC, Cheyenne Services SRL, Statistics Netherlands and were funded by Ministry of Public Health (former Ministry of Health) with supplemental support of Eli Lilly Romania SRL. The Saudi National Mental Health

Survey (SNMHS) is conducted by the King Salman Center for Disability Research. It is funded by Saudi Basic Industries Corporation (SABIC), King Abdulaziz City for Science and Technology (KACST), Ministry of Health (Saudi Arabia), and King Saud University. Funding in-kind was provided by King Faisal Specialist Hospital and Research Center, and the Ministry of Economy and Planning, General Authority for Statistics. The Psychiatric Enquiry to General Population in Southeast Spain – Murcia (PEGASUS-Murcia) Project has been financed by the Regional Health Authorities of Murcia (Servicio Murciano de Salud and Consejería de Sanidad y Política Social) and Fundación para la Formación e Investigación Sanitarias (FFIS) of Murcia. The US National Comorbidity Survey Replication (NCS-R) is supported by the National Institute of Mental Health (NIMH; U01-MH60220) with supplemental support from the National Institute of Drug Abuse (NIDA), the Substance Abuse and Mental Health Services Administration (SAMHSA), the Robert Wood Johnson Foundation (RWJF; Grant 044708), and the John W. Alden Trust.

Dr. Stein is supported by the Medical Research Council of South Africa (MRC).

WMH COLLABORATORS

The WHO World Mental Health Survey collaborators are Sergio Aguilar-Gaxiola, MD, PhD; Ali Al-Hamzawi, MD; Mohammed Salih Al-Kaisy, MD; Jordi Alonso, MD, PhD; Laura Helena Andrade, MD, PhD; Lukoye Atwoli, MD, PhD; Corina Benjet, PhD; Guilherme Borges, ScD; Evelyn J. Bromet, PhD; Ronny Bruffaerts, PhD; Brendan Bunting, PhD; Jose Miguel Caldas-de-Almeida, MD, PhD; Graça Cardoso, MD, PhD; Somnath Chatterji, MD; Alfredo H. Cia, MD; Louisa Degenhardt, PhD; Koen Demyttenaere, MD, PhD; Silvia Florescu, MD, PhD; Giovanni de Girolamo, MD; Oye Gureje, MD, DSc, FRCPsych; Josep; Maria Haro, MD, PhD; Meredith Harris, PhD; Hristo Hinkov, MD, PhD; Chi-yi Hu, MD, PhD; Peter de Jonge, PhD; Aimee Nasser Karam, PhD; Elie G. Karam, MD; Norito Kawakami, MD, DMSc; Ronald C. Kessler, PhD; Andrzej Kiejna, MD, PhD; Viviane Kovess-Masfety, MD, PhD; Sing Lee, MB, BS; Jean-Pierre Lepine, MD; John McGrath, MD, PhD; Maria Elena Medina-Mora, PhD; Zeina Mneimneh, PhD; Jacek Moskalewicz, PhD; Fernando Navarro-Mateu, MD, PhD; Marina Piazza, MPH, ScD; Jose Posada-Villa, MD; Kate M. Scott, PhD; Tim Slade, PhD; Juan Carlos Stagnaro, MD, PhD; Dan J. Stein, FRCPC, PhD; Margreet ten Have, PhD; Yolanda Torres, MPH, Dra.HC; Maria Carmen Viana, MD, PhD; Daniel Vigo, MD, DrPH; Harvey Whiteford, MBBS, PhD; David R. Williams, MPH, PhD; Bogdan Wojtyniak, ScD.

DATA AVAILABILITY STATEMENT

Access to the cross-national World Mental Health (WMH) data is governed by the organizations funding and responsible for survey data collection in each country. These organizations made data available to the WMH consortium through restricted data sharing agreements that do not allow us to release the data to third parties. The exception is that the U.S. data are available for secondary analysis via the Inter-University Consortium for Political and Social Research (ICPSR), <http://www.icpsr.umich.edu/icpsrweb/ICPSR/series/00527>.

CONFLICT OF INTERESTS

Dr. Navarro-Mateu reports nonfinancial support from Otsuka outside the submitted work. In the past 3 years, Dr. Kessler received support for his epidemiological studies from Sanofi Aventis; was a consultant for Datastat, Inc., Sage Pharmaceuticals, and Takeda. Dr. Stein has received research grants and/or honoraria from Lundbeck and Sun.

ORCID

Jordi Alonso  <http://orcid.org/0000-0001-8627-9636>

Ronald C. Kessler  <http://orcid.org/0000-0003-4831-2305>

REFERENCES

- Alegria, M., Jackson, J. S., Kessler, R. C., Takeuchi, D. (2016). *Collaborative Psychiatric Epidemiology Surveys (CPES), 2001-2003* [United States], Inter-university Consortium for Political and Social Research. <https://doi.org/10.3886/ICPSR20240.v8>
- Barsky, A. J. (2002). Forgetting, fabricating, and telescoping: The instability of the medical history. *Archives of Internal Medicine*, 162, 981–984. <https://doi.org/10.1001/archinte.162.9.981>
- Bellamy, C. D., Flanagan, H. E., Costa, M., O'Connell-Bonarrigo, M., Tana Le, T., Guy, K., ... Steiner, J. L. (2016). Barriers and facilitators of healthcare for people with mental illness: Why integrated patient centered healthcare is necessary. *Issues in Mental Health Nursing*, 37, 421–428. <https://doi.org/10.3109/01612840.2016.1162882>
- Benjet, C., Bromet, E., Karam, E. G., Kessler, R. C., McLaughlin, K. A., Ruscio, A. M., ... Koenen, K. C. (2016). The epidemiology of traumatic event exposure worldwide: Results from the World Mental Health Survey Consortium. *Psychological Medicine*, 46, 327–343. <https://doi.org/10.1017/S0033291715001981>
- Bromet, E., Karam, E., Koenen, K. & Stein, D. (Eds.). (2018). *Trauma and posttraumatic stress disorder: Global perspectives from the WHO World Mental Health Surveys*. Cambridge, UK: Cambridge University Press.
- Charney, M. E., Hellberg, S. N., Bui, E., & Simon, N. M. (2018). Evidenced-based treatment of posttraumatic stress disorder: An updated review of validated psychotherapeutic and pharmacological approaches. *Harvard Review of Psychiatry*, 26, 99–115. <https://doi.org/10.1097/hrp.000000000000186>
- Cooper, A. A., Kline, A. C., Graham, B., Bedard-Gilligan, M., Mello, P. G., Feeny, N. C., & Zoellner, L. A. (2017). Homework “dose,” type, and helpfulness as predictors of clinical outcomes in prolonged exposure for PTSD. *Behavior Therapy*, 48, 182–194. <https://doi.org/10.1016/j.beth.2016.02.013>
- Difede, J., Olden, M., & Cukor, J. (2014). Evidence-based treatment of post-traumatic stress disorder. *Annual Review of Medicine*, 65, 319–332. <https://doi.org/10.1146/annurev-med-051812-145438>
- Etingen, B., Hill, J. N., Miller, L. J., Schwartz, A., LaVela, S. L., & Jordan, N. (2019). An exploratory pilot study to describe shared decision-making for PTSD treatment planning: The provider perspective. *Military Medicine*, 184, 467–475. <https://doi.org/10.1093/milmed/usy407>
- Fagiolini, A., Rocca, P., De Giorgi, S., Spina, E., Amodeo, G., & Amore, M. (2017). Clinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: Randomized controlled trials vs naturalistic studies. *Psychiatry Research*, 247, 257–264. <https://doi.org/10.1016/j.psychres.2016.11.044>
- First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. W. (2002). *Structured clinical interview for DSM-IV Axis I disorders, research version, non-patient edition (SCID-I/NP)*. New York, NY: Biometrics Research, New York State Psychiatric Institute.
- Fortney, J. C., Unutzer, J., Wrenn, G., Pyne, J. M., Smith, G. R., Schoenbaum, M., & Harbin, H. T. (2017). A tipping point for measurement-based care. *Psychiatric Services*, 68, 179–188. <https://doi.org/10.1176/appi.ps.201500439>

- Halli, S. S., & Rao, K. V. (1992). *Advanced techniques of population analysis*. New York, NY: Plenum.
- Harkness, J., Pennell, B. E., Villar, A., Gebler, N., Aguilar-Gaxiola, S., & Bilgen, I. (2008). Translation procedures and translation assessment in the World Mental Health Survey Initiative. In R. C. Kessler & T. B. Ustün (Eds.), *The WHO World Mental Health Surveys: Global perspectives on the epidemiology of mental disorders* (pp. 91–113). Cambridge, UK: Cambridge University Press.
- Haro, J. M., Arbabzadeh-Bouchez, S., Brugha, T. S., de Girolamo, G., Guyer, M. E., Jin, R., ... Kessler, R. C. (2006). Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO World Mental Health Surveys. *International Journal of Methods in Psychiatric Research*, 15, 167–180. <https://doi.org/10.1002/mpr.196>
- Heeringa, S. G., Wells, J. E., Hubbard, F., Mneimneh, Z. N., Chiu, W. T., Sampson, N. A., & Berglund, P. A. (2008). Sample designs and sampling procedures. In R. C. Kessler & T. B. Ustün (Eds.), *The WHO World Mental Health Surveys: Global perspectives on the epidemiology of mental disorders* (pp. 14–32). Cambridge, UK: Cambridge University Press.
- Janiaud, P., Dal-Re, R., & Ioannidis, J. P. A. (2018). Assessment of pragmatism in recently published randomized clinical trials. *JAMA Internal Medicine*, 178, 1278–1280. <https://doi.org/10.1001/jamainternmed.2018.3321>
- Karam, E. G., Andrews, G., Bromet, E., Petukhova, M., Ruscio, A. M., Salamoun, M., ... Kessler, R. C. (2010). The role of criterion A2 in the DSM-IV diagnosis of posttraumatic stress disorder. *Biological Psychiatry*, 68, 465–473. <https://doi.org/10.1016/j.biopsych.2010.04.032>
- Kessler, R. C., Aguilar-Gaxiola, S., Alonso, J., Benjet, C., Bromet, E. J., Cardoso, G., ... Koenen, K. C. (2017). Trauma and PTSD in the WHO World Mental Health Surveys. *European Journal of Psychotraumatology*, 8, 1353383. <https://doi.org/10.1080/20008198.2017.1353383>
- Kessler, R. C., Aguilar-Gaxiola, S., Alonso, J., Lee, S., & Koenen, K. C. (2018). The population burden of posttraumatic stress disorder. In E. J. Bromet, E. G. Karam, K. C. Koenen & D. J. Stein (Eds.), *Trauma and posttraumatic stress disorder: Global perspectives from the WHO World Mental Health Surveys* (pp. 318–324). Cambridge, UK: Cambridge University Press.
- Kessler, R. C., Bossarte, R. M., Luedtke, A., Zaslavsky, A. M., & Zubizarreta, J. R. (2019). Machine learning methods for developing precision treatment rules with observational data. *Behavior Research and Therapy*, 120, 103412. <https://doi.org/10.1016/j.brat.2019.103412>
- Kessler, R. C., Ormel, J., Petukhova, M., McLaughlin, K. A., Green, J. G., Russo, L. J., ... Ustün, T. B. (2011). Development of lifetime comorbidity in the World Health Organization World Mental Health Surveys. *Archives of General Psychiatry*, 68, 90–100. <https://doi.org/10.1001/archgenpsychiatry.2010.180>
- Kessler, R. C., & Ustün, T. B. (2004). The World Mental Health (WMH) Survey Initiative version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). *International Journal of Methods in Psychiatric Research*, 13, 93–121. <https://doi.org/10.1002/mpr.168>
- Maj, M. (2020). Helpful treatment of depression—Delivering the right messages. *JAMA Psychiatry*, <https://doi.org/10.1001/jamapsychiatry.2020.0363>
- Marshall, R. D., Schneier, F. R., Fallon, B. A., Knight, C. B., Abbate, L. A., Goetz, D., ... Liebowitz, M. R. (1998). An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. *Journal of Clinical Psychopharmacology*, 18, 10–18. <https://doi.org/10.1097/00004714-199802000-00003>
- Najavits, L. M., Rynkala, D., Back, S. E., Bolton, E., Mueser, K. T., & Brady, K. T. (2009). Treatment of PTSD and comorbid disorders. In E. B. Foa, T. M. Keane, M. J. Friedman & J. A. Cohen (Eds.), *Effective treatments for PTSD: Practice guidelines from the International Society for Traumatic Stress Studies* (2nd ed., pp. 508–538). New York, NY: Guilford Press.
- Oades, L. G., Law, J., & Marshall, S. L. (2011). Development of a consumer constructed scale to evaluate mental health service provision. *Journal of Evaluation in Clinical Practice*, 17, 1102–1107. <https://doi.org/10.1111/j.1365-2753.2010.01474.x>
- Patel, V., Saxena, S., Lund, C., Thornicroft, G., Baingana, F., Bolton, P., ... Unutzer, J. (2018). The Lancet Commission on global mental health and sustainable development. *Lancet*, 392, 1553–1598. [https://doi.org/10.1016/s0140-6736\(18\)31612-x](https://doi.org/10.1016/s0140-6736(18)31612-x)
- SAS Institute Inc. (2016). SAS/STAT® 14.3 software version 9.4 for unix [computer program]. (Version 9.4). Cary, NC.
- Scott, K. M., Lim, C., Al-Hamzawi, A., Alonso, J., Bruffaerts, R., Caldas-de-Almeida, J. M., ... Kessler, R. C. (2016). Association of mental disorders with subsequent chronic physical conditions: World Mental Health Surveys from 17 countries. *JAMA Psychiatry*, 73, 150–158. <https://doi.org/10.1001/jamapsychiatry.2015.2688>
- Seymour, C. W., Gomez, H., Chang, C. H., Clermont, G., Kellum, J. A., Kennedy, J., ... Angus, D. C. (2017). Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness. *Critical Care*, 21, 257. <https://doi.org/10.1186/s13054-017-1836-5>
- Sharma, T., Bamford, M., & Dodman, D. (2015). Person-centred care: An overview of reviews. *Contemporary Nurse*, 51, 107–120. <https://doi.org/10.1080/10376178.2016.1150192>
- Starzynski, L. L., & Ullman, S. E. (2014). Correlates of perceived helpfulness of mental health professionals following disclosure of sexual assault. *Violence Against Women*, 20, 74–94. <https://doi.org/10.1177/1077801213520575>
- Stein, D. J., Bass, J., & Hofmann, S. (2019). *Global mental health and psychotherapy: Adapting psychotherapy for low- and middle-income countries*. London, UK: Elsevier Inc.
- Stein, D. J., Koenen, K. C., Friedman, M. J., Hill, E., McLaughlin, K. A., Petukhova, M., ... Kessler, R. C. (2013). Dissociation in posttraumatic stress disorder: Evidence from the World Mental Health Surveys. *Biological Psychiatry*, 73, 302–312. <https://doi.org/10.1016/j.biopsych.2012.08.022>
- Stein, D. J., McLaughlin, K. A., Koenen, K. C., Atwoli, L., Friedman, M. J., Hill, E. D., ... Kessler, R. C. (2014). DSM-5 and ICD-11 definitions of posttraumatic stress disorder: Investigating “narrow” and “broad” approaches. *Depression and Anxiety*, 31, 494–505. <https://doi.org/10.1002/da.22279>
- Thornicroft, G., Evans-Lacko, S., Koenen, K. C., Kovess-Masfety, V., Williams, D. R., & Kessler, R. C. (2018). Patterns of treatment and barriers to care in posttraumatic stress disorder. In E. J. Bromet, E. G. Karam, K. C. Koenen & D. J. Stein (Eds.), *Trauma and posttraumatic stress disorder: Global perspectives from the WHO World Mental Health Surveys* (pp. 137–152). Cambridge, UK: Cambridge University Press.
- Uttaro, T. (2003). The development and administration of the consumer assessments of care by New York State Office of Mental Health downstate facilities. *Evaluation and Program Planning*, 26, 143–147. [https://doi.org/10.1016/s0149-7189\(03\)00011-9](https://doi.org/10.1016/s0149-7189(03)00011-9)
- Willett, J. B., & Singer, J. D. (1993). Investigating onset, cessation, relapse, and recovery: Why you should, and how you can, use discrete-time survival analysis to examine event occurrence. *Journal of Consulting and Clinical Psychology*, 61, 952–965. <https://doi.org/10.1037/0022-006x.61.6.952>
- Wolter, K. (1985). *Introduction to variance estimation*. New York, NY: Springer-Verlag.
- World Health Organization. (2020). WHO Mental Health Gap Action Programme (mhGAP). Retrieved from https://www.who.int/mental_health/mhgap/en/

How to cite this article: Stein DJ, Harris MG, Vigo DV, et al. Perceived helpfulness of treatment for posttraumatic stress disorder: Findings from the World Mental Health Surveys. *Depress Anxiety*. 2020;1–23. <https://doi.org/10.1002/da.23076>

APPENDIX A

TABLE A1 WMH sample characteristics by World Bank income categories^a

Country by income category	Survey ^b	Sample characteristics ^c	Field dates	Age range	Part I	Part II	Part II and age ≤44 ^d	Response rate ^e
I. Low/middle-income countries								
Brazil – São Paulo	São Paulo Megacity	São Paulo metropolitan area	2005–8	18–93	5,037	2,942	–	81.3
Bulgaria	NSHS 2002–6	Nationally representative	2002–6	18–98	5,318	2,233	741	72.0
Bulgaria 2	NNSHS 2016–17	Nationally representative	2016–17	18–91	1,508	578	–	61.0
Colombia	NSMH	All urban areas of the country (approximately 73% of the total national population)	2003	18–65	4,426	2,381	1,731	87.7
Colombia – Medellín	MMHHS	Medellín metropolitan area	2011–12	19–65	3,261	1,673	–	97.2
Lebanon	LEBANON	Nationally representative	2002–3	18–94	2,857	1,031	595	70.0
Mexico	M-NCS	All urban areas of the country (approximately 75% of the total national population)	2001–2	18–65	5,782	2,362	1,736	76.6
Romania	RMHS	Nationally representative	2005–6	18–96	2,357 (30,546)	2,357 (15,557)	– (4,803)	70.9 77.2
Total								
II. High-income countries								
Argentina	AMHES	Eight largest urban areas of the country (approximately 50% of the total national population)	2015	18–98	3,927	2,116	–	77.3
Australia ^f	NSMHWB	Nationally representative	2007	18–85	8,463	8,463	–	60.0
Israel	NHS	Nationally representative	2003–4	21–98	4,859	4,859	–	72.6
Japan	WMHJ 2002–6	Eleven metropolitan areas	2002–6	20–98	4,129	1,682	–	55.1
New Zealand ^f	NZMHS	Nationally representative	2004–5	18–98	12,790	7,312	–	73.3
Northern Ireland	NISHS	Nationally representative	2005–8	18–97	4,340	1,986	–	68.4
Portugal	NMHS	Nationally representative	2008–9	18–81	3,849	2,060	1,070	57.3
Saudi Arabia ^f	SNMHS	Nationally representative	2013–16	18–65	3,638	1,793	–	61.0
Spain – Murcia	PEGASUS-Murcia	Murcia region. Regionally representative	2010–12	18–96	2,621	1,459	–	67.4
United States	NCS-R	Nationally representative	2001–3	18–99	9,282	5,692	3,197	70.9

(Continues)

TABLE A1 (Continued)

Country by income category	Survey ^b	Sample characteristics ^c	Field dates	Age range	Part I	Part II	Part II and age $\leq 44^d$	Response rate ^e
Total					(57,898)	(37,422)	(4,267)	66.7
III. Total					(88,444)	(52,979)	(9,070)	70.1

^aThe World Bank (2012) Data. Accessed May 12, 2012 at <http://data.worldbank.org/country>. Some of the WMH countries have moved into new income categories since the surveys were conducted. The income groupings above reflect the status of each country at the time of data collection. The current income category of each country is available at the preceding URL.

^bNSHS (Bulgaria National Survey of Health and Stress); NSMH (The Colombian National Study of Mental Health); MMHS (Romania Mental Health Household Study); LEBANON (Lebanese Evaluation of the Burden of Ailments and Needs of the Nation); M-NCS (The Mexico National Comorbidity Survey); RMHS (Romania Mental Health Survey); AMHES (Argentina Mental Health Epidemiologic Survey); NSMHWB (National Survey of Mental Health and Wellbeing); NHS (Israel National Health Survey); WMHJ2002-2006 (World Mental Health Japan Survey); NZMHS (New Zealand Mental Health Survey); NISHS (Northern Ireland Study of Health and Stress); NMHS (Portugal National Mental Health Survey); SNMHS (Saudi National Mental Health Survey); PEGASUS-Murcia (Psychiatric Enquiry to General Population in Southeast Spain-Murcia); NCS-R (The US National Comorbidity Survey Replication).

^cMost WMH surveys are based on stratified multistage clustered area probability household samples in which samples of areas equivalent to counties or municipalities in the US were selected in the first stage followed by one or more subsequent stages of geographic sampling (e.g., towns within counties, blocks within towns, households within blocks) to arrive at a sample of households, in each of which a listing of household members was created and one or two people were selected from this listing to be interviewed. No substitution was allowed when the originally sampled household resident could not be interviewed. These household samples were selected from Census area data in most countries. In Spain-Murcia, the universal health-care registries were used to select respondents without listing households. The Japanese sample is the only totally un-clustered sample, with households randomly selected in each of the 11 metropolitan areas and one random respondent selected in each sample household. 11 of the 48 surveys are based on nationally representative household samples.

^dArgentina, Australia, Brazil, Bulgaria 2 (2016-17), Colombia-Medellin, Israel, Japan, New Zealand, Northern Ireland, Romania, Saudi Arabia, and Spain-Murcia did not have an age restricted Part 2 sample. All other countries were age restricted to ≤ 44 .

^eThe response rate is calculated as the ratio of the number of households in which an interview was completed to the number of households originally sampled, excluding from the denominator households known not to be eligible either because of being vacant at the time of initial contact or because the residents were unable to speak the designated languages of the survey. The weighted average response rate is 70.1%.

^fFor the purposes of cross-national comparisons we limit the sample to those 18+.

TABLE A2 Conditional and cumulative probabilities of PTSD treatment being perceived as helpful after each professional seen, among respondents with lifetime DSM-IV PTSD who obtained treatment

	I. Conditional probabilities									II. Cumulative probabilities					
	All			High-income countries			Low/middle-income countries			All (n = 779)		High-income countries (n = 726)		Low/middle-income countries (n = 53)	
	%	(SE)	(n)	%	(SE)	(n)	%	(SE)	(n)	%	(SE)	%	(SE)	%	(SE)
Number of professionals seen after which treatment was perceived as helpful															
1	24.0	(2.3)	(779)	23.8	(2.4)	(726)	27.7	(2.4)	(53)	24.0	(2.3)	23.8	(2.4)	27.7	(2.4)
2	32.7	(2.8)	(417)	33.2	(2.9)	(395)	19.4	(6.0)	(22)	48.8	(2.8)	49.1	(2.9)	41.7	(10.2)
3	31.4	(3.7)	(198)	32.5	(3.9)	(183)	12.0	(1.1)	(15)	64.9	(2.9)	65.6	(3.0)	48.7	(10.9)
4	30.1	(7.9)	(97)	30.4	(8.1)	(93)	21.0	(16.6)	(4)	75.5	(2.9)	76.1	(2.9)	59.5	(15.2)
5	22.7	(5.8)	(57)	23.2	(6.0)	(55)	0.0	(0.0)	(2)	81.1	(2.8)	81.6	(2.7)	-	
6	24.8	(7.0)	(40)	25.5	(7.2)	(38)	0.0	(0.0)	(2)	85.7	(2.6)	86.3	(2.6)	-	
7	23.0	(8.6)	(26)	24.2	(9.0)	(24)	0.0	(0.0)	(2)	89.0	(2.2)	89.6	(2.2)	-	
8	64.2	(9.0)	(22)	68.7	(9.2)	(20)	0.0	(0.0)	(2)	96.1	(1.4)	96.7	(1.3)	-	
9	0.0	(0.0)	(8)	0.0	(0.0)	(6)	0.0	(0.0)	(2)	-	-	-	-	-	
10	37.8	(10.4)	(8)	47.1	(16.1)	(6)	0.0	(0.0)	(2)	97.6	(1.2)	98.3	(1.1)	-	
11	0.0	(0.0)	(5)	0.0	(0.0)	(3)	0.0	(0.0)	(2)	-	-	-	-	-	
12	0.0	(0.0)	(5)	0.0	(0.0)	(3)	0.0	(0.0)	(2)	-	-	-	-	-	
13	0.0	(0.0)	(5)	0.0	(0.0)	(3)	0.0	(0.0)	(2)	-	-	-	-	-	
14	0.0	(0.0)	(5)	0.0	(0.0)	(3)	0.0	(0.0)	(2)	-	-	-	-	-	
15	0.0	(0.0)	(5)	0.0	(0.0)	(3)	0.0	(0.0)	(2)	-	-	-	-	-	
16	0.0	(0.0)	(5)	0.0	(0.0)	(3)	0.0	(0.0)	(2)	-	-	-	-	-	
17	0.0	(0.0)	(5)	0.0	(0.0)	(3)	0.0	(0.0)	(2)	-	-	-	-	-	
18	0.0	(0.0)	(5)	0.0	(0.0)	(3)	0.0	(0.0)	(2)	-	-	-	-	-	
19	0.0	(0.0)	(5)	0.0	(0.0)	(3)	0.0	(0.0)	(2)	-	-	-	-	-	
20	61.3	(17.4)	(5)	89.7	(11.4)	(3)	0.0	(0.0)	(2)	99.1	(0.6)	99.8	(0.2)	-	
21	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	
22	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	
23	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	
24	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	
25	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	
26	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	
27	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	
28	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	
29	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	
30	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	
31	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	
32	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	
33	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	
34	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	
35	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	
36	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	

(Continues)

TABLE A2 (Continued)

	I. Conditional probabilities									II. Cumulative probabilities					
	All			High-income countries			Low/middle-income countries			All (n = 779)		High-income countries (n = 726)		Low/middle-income countries (n = 53)	
	%	(SE)	(n)	%	(SE)	(n)	%	(SE)	(n)	%	(SE)	%	(SE)	%	(SE)
37	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	-
38	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	-
39	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	-
40	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	-
41	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	-
42	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	-
43	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	-
44	0.0	(0.0)	(2)	-			0.0	(0.0)	(2)	-	-	-	-	-	-
45	42.0	(0.0)	(2)	-			42.0	(0.0)	(2)	99.5	(0.5)	-	-	76.5	(16.9)
46	0.0	(0.0)	(1)	-			0.0	(0.0)	(1)	-	-	-	-	-	-
47	0.0	(0.0)	(1)	-			0.0	(0.0)	(1)	-	-	-	-	-	-
48	0.0	(0.0)	(1)	-			0.0	(0.0)	(1)	-	-	-	-	-	-
49	100.0	(0.0)	(1)	-			100.0	(0.0)	(1)	100.0	(0.0)	-	-	100.0	(0.0)

Abbreviations: PTSD, posttraumatic stress disorder; SE, standard error.

TABLE A3 Conditional and cumulative probability of persistence with treatment after previous unhelpful attempts, among respondents with lifetime DSM-IV PTSD who obtained treatment

	I. Conditional probabilities									II. Cumulative probabilities					
	All			High-income countries			Low/middle income countries			All (n = 616)		High-income countries (n = 580)		Low/middle-income countries (n = 36)	
	%	(SE)	(n)	%	(SE)	(n)	%	(SE)	(n)	%	(SE)	%	(SE)	%	(SE)
Number of professionals seen if not helped by the previous one															
2	67.9	(2.0)	(616)	68.3	(2.1)	(580)	58.0	(2.6)	(36)	67.9	(2.0)	68.3	(2.1)	58.0	(2.6)
3	70.6	(3.0)	(281)	70.0	(3.1)	(263)	84.1	(3.1)	(18)	48.0	(3.0)	47.9	(3.1)	48.8	(11.0)
4	65.6	(3.5)	(145)	68.2	(3.6)	(132)	27.3	(4.2)	(13)	31.5	(3.0)	32.7	(3.1)	13.3	(6.9)
5	81.1	(4.4)	(73)	81.8	(4.6)	(70)	57.9	(0.0)	(3)	25.5	(3.0)	26.7	(3.2)	7.7	(5.4)
6	92.5	(5.1)	(43)	92.2	(5.2)	(41)	100.0	(0.0)	(2)	23.6	(3.1)	24.7	(3.3)	-	-
7	80.2	(8.9)	(30)	79.4	(9.3)	(28)	100.0	(0.0)	(2)	18.9	(3.2)	19.6	(3.4)	-	-
8	100.0	(0.0)	(22)	100.0	(0.0)	(20)	100.0	(0.0)	(2)	-	-	-	-	-	-
9	91.9	(4.3)	(10)	90.1	(5.5)	(8)	100.0	(0.0)	(2)	17.4	(3.2)	17.6	(3.5)	-	-
10	100.0	(0.0)	(8)	100.0	(0.0)	(6)	100.0	(0.0)	(2)	-	-	-	-	-	-
11	100.0	(0.0)	(5)	100.0	(0.0)	(3)	100.0	(0.0)	(2)	-	-	-	-	-	-
12	100.0	(0.0)	(5)	100.0	(0.0)	(3)	100.0	(0.0)	(2)	-	-	-	-	-	-
13	100.0	(0.0)	(5)	100.0	(0.0)	(3)	100.0	(0.0)	(2)	-	-	-	-	-	-
14	100.0	(0.0)	(5)	100.0	(0.0)	(3)	100.0	(0.0)	(2)	-	-	-	-	-	-
15	100.0	(0.0)	(5)	100.0	(0.0)	(3)	100.0	(0.0)	(2)	-	-	-	-	-	-

TABLE A3 (Continued)

	I. Conditional probabilities									II. Cumulative probabilities					
	All			High-income countries			Low/middle income countries			All (n = 616)		High-income countries (n = 580)		Low/middle-income countries (n = 36)	
	%	(SE)	(n)	%	(SE)	(n)	%	(SE)	(n)	%	(SE)	%	(SE)	%	(SE)
16	100.0	(0.0)	(5)	100.0	(0.0)	(3)	100.0	(0.0)	(2)	-	-	-	-	-	-
17	100.0	(0.0)	(5)	100.0	(0.0)	(3)	100.0	(0.0)	(2)	-	-	-	-	-	-
18	100.0	(0.0)	(5)	100.0	(0.0)	(3)	100.0	(0.0)	(2)	-	-	-	-	-	-
19	100.0	(0.0)	(5)	100.0	(0.0)	(3)	100.0	(0.0)	(2)	-	-	-	-	-	-
20	100.0	(0.0)	(5)	100.0	(0.0)	(3)	100.0	(0.0)	(2)	-	-	-	-	-	-
21	81.8	(14.9)	(3)	0.0	(0.0)	(1)	100.0	(0.0)	(2)	14.2	(4.3)	0.0	(0.0)	-	-
22	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
23	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
24	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
25	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
26	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
27	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
28	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
29	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
30	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
31	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
32	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
33	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
34	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
35	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
36	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
37	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
38	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
39	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
40	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
41	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
42	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
43	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
44	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
45	100.0	(0.0)	(2)	-	-	-	100.0	(0.0)	(2)	-	-	-	-	-	-
46	100.0	(0.0)	(1)	-	-	-	100.0	(0.0)	(1)	-	-	-	-	-	-
47	100.0	(0.0)	(1)	-	-	-	100.0	(0.0)	(1)	-	-	-	-	-	-
48	100.0	(0.0)	(1)	-	-	-	100.0	(0.0)	(1)	-	-	-	-	-	-
49	100.0	(0.0)	(1)	-	-	-	100.0	(0.0)	(1)	-	-	-	-	-	-

Abbreviations: PTSD, posttraumatic stress disorder; SE, standard error.

TABLE A4 (Reduced predictors) Predictors of helpful treatment and persistence (pooled across professionals seen), and predictors of perceived helpfulness of treatment (person level), among people with lifetime DSM-IV PTSD who obtained treatment

	Model 1: Predicting helpful treatment pooled across professionals seen			Model 2: Predicting persistence pooled across treatment failure			Model 3: Predicting perceived helpfulness of treatment across PTSD patients					
	Prevalence		Multivariate	Prevalence		Multivariate	Prevalence		Multivariate			
	Mean/%	(SE)	AOR	(95% CI)	Mean/%	(SE)	AOR	(95% CI)	Mean/%	(SE)	AOR	(95% CI)
Age at first posttraumatic stress treatment	35.0	(0.7)	1.00	(0.99–1.01)	35.2	(0.8)	1.00	(0.99–1.01)	35.5	(0.6)	1.00	(0.99–1.02)
χ^2_1			0.65					0.01			0.33	
Treatment delay (years) ^a	9.2	(0.7)	0.99*	(0.97–1.00)	9.6	(0.8)	0.98*	(0.97–0.99)	9.7	(0.6)	0.98*	(0.96–0.99)
χ^2_1			3.97*				7.52*				7.46*	
Started PTSD treatment \geq 2000 (vs. 1990–1999)	57.2	(2.4)	0.87*	(0.65–1.16)	57.5	(2.7)	0.50*	(0.33–0.75)	62.6	(2.0)	0.45*	(0.29–0.71)
χ^2_1			0.90				11.51*				11.66*	
Treatment type ^b												
Mental health specialist + Psychotherapy	51.9	(2.5)	1.42	(0.96–2.10)	52.5	(2.7)	1.55	(0.93–2.58)	51.0	(2.2)	2.06*	(1.21–3.50)
Mental health specialist + Medication	68.1	(2.3)	1.35	(0.87–2.08)	68.3	(2.5)	1.92*	(1.30–2.85)	60.2	(2.4)	2.17*	(1.26–3.74)
General medical	80.8	(1.6)	0.75	(0.53–1.05)	82.0	(1.6)	1.71*	(1.09–2.68)	76.3	(1.8)	1.12	(0.64–1.98)
Complementary/alternative medicine	26.6	(2.0)	1.08	(0.77–1.51)	27.5	(2.2)	0.78	(0.54–1.13)	24.5	(2.0)	0.94	(0.59–1.53)
Human services	24.9	(2.4)	1.00	–	26.5	(2.7)	1.00	–	22.9	(2.1)	1.00	–
χ^2_4			10.28*				17.92*				12.52*	
Exactly 2 or more types of treatment	79.6	(1.7)	0.60	(0.33–1.11)	80.5	(1.8)	1.34	(0.73–2.45)	72.2	(2.0)	0.82	(0.40–1.67)
χ^2_1			2.67				0.90				0.31	
χ^2_5			11.51*				43.54*				23.38*	
Number of lifetime anxiety disorders ^c												
3+ ^c	34.4	(2.4)	0.91	(0.65–1.27)	35.9	(2.6)	1.47	(0.97–2.22)	28.3	(1.9)	1.38	(0.88–2.14)
2 ^c	28.4	(2.2)	0.68*	(0.47–0.98)	29.3	(2.5)	0.75	(0.50–1.11)	30.7	(2.1)	0.55*	(0.35–0.88)
1 ^c	37.2	(2.5)	1.00	–	34.8	(2.7)	1.00	–	40.9	(2.3)	1.00	–
χ^2_2			6.13*				11.88*				19.59*	
Traumatic events implicated in the PTSD												
Exposure to organized violence ^d	15.8	(1.9)	0.63*	(0.41–0.97)	16.9	(2.0)	1.18	(0.78–1.79)	14.3	(1.5)	0.80	(0.44–1.43)

TABLE A4 (Continued)

	Model 1: Predicting helpful treatment pooled across professionals seen			Model 2: Predicting persistence pooled across treatment failure			Model 3: Predicting perceived helpfulness of treatment across PTSD patients					
	Prevalence	Multivariate		Prevalence	Multivariate		Prevalence	Multivariate				
	Mean/%	(SE)	AOR	(95% CI)	Mean/%	(SE)	AOR	(95% CI)	Mean/%	(SE)	AOR	(95% CI)
Participation in organized violence ^e	44.0	(2.6)	1.16	(0.88–1.52)	44.7	(2.8)	1.11	(0.76–1.62)	41.9	(2.3)	1.08	(0.73–1.59)
Physical violence victimization ^f	33.7	(2.4)	0.58*	(0.43–0.79)	35.7	(2.6)	1.47*	(1.02–2.11)	27.4	(2.2)	0.75	(0.46–1.21)
Sexual violence victimization ^g	63.7	(2.2)	1.36*	(1.02–1.82)	63.1	(2.4)	1.05	(0.76–1.45)	63.0	(2.1)	1.43	(0.98–2.09)
Accidents/injuries ^h	51.3	(2.7)	0.96	(0.69–1.35)	53.1	(3.0)	1.17	(0.80–1.71)	48.7	(2.0)	1.00	(0.66–1.52)
Other ⁱ	66.7	(2.5)	0.96	(0.72–1.27)	67.7	(2.7)	0.95	(0.65–1.39)	64.5	(2.2)	0.97	(0.64–1.47)
χ^2_2			24.23*				9.09				4.91	
Childhood adversities												
Family dysfunction ^j	30.8	(1.7)	0.80	(0.58–1.10)	34.0	(2.0)	0.85	(0.62–1.18)	29.6	(1.5)	0.70	(0.47–1.05)
Other ^k	12.9	(1.1)	0.77	(0.54–1.08)	14.3	(1.2)	0.51*	(0.37–0.71)	16.0	(1.2)	0.41*	(0.28–0.60)
χ^2_2			4.23				20.89*				22.12*	
Global χ^2_{18}			64.39*				155.96*				89.00*	

Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; PTSD, posttraumatic stress disorder; SE, standard error.

^aTreatment delay (years) = Age at first PTSD treatment – Age at onset of PTSD.

^bTreatment providers: mental health specialists (psychiatrist, psychiatric nurse, psychologist, psychiatric social worker, mental health counselor), primary care providers, human services providers (social worker or counselor in a social services agency, spiritual advisor), and complementary/alternative medicine (other type of healer or self-help group).

^cLifetime anxiety disorders include generalized anxiety disorder, panic disorder, agoraphobia with or without panic disorder, posttraumatic stress disorder, specific phobia and social phobia.

^dExposure to organized violence includes relief worker in war zone, civilian in war zone, civilian in region of terror, refugee and kidnapped.

^eParticipation in organized violence includes witnessed death/dead body/serious injury, accidentally caused serious injury/death, combat experience, purposely injured/tortured/killed someone and witnessed atrocities.

^fPhysical violence victimization includes beaten by caregiver, beaten by someone else and witnessed physical fight at home.

^gSexual violence victimization includes raped, sexually assaulted, stalked, beaten by spouse/romantic partner, trauma to loved one, some other trauma and private trauma.

^hAccidents/injuries includes natural disaster, toxic chemical exposure, automobile accident, life-threatening illness, child with serious illness and other life-threatening accident.

ⁱOther includes mugged/threatened with a weapon, human-made disaster and unexpected death of a loved one.

^jFamily dysfunction includes physical abuse, sexual abuse, neglect, parent mental disorder, parent substance use disorder, parent criminal behavior and family violence. Percentages represent the proportions of respondents with one or more of these childhood adversities.

^kOther childhood adversities include parent died, parent divorced, other parent loss, physical illness and economic adversity. Percentages represent the proportions of respondents with one or more of these childhood adversities.

*Significant at .05 level, two-sided test.

TABLE A5 Interaction between main effects and historical time to predict helpful treatment and persistence (pooled across professionals seen), and predictors of perceived helpfulness of treatment (person level), among people with lifetime DSM-IV PTSD who obtained treatment

	Model 1: Predicting helpful treatment pooled across professionals seen			Model 2: Predicting persistence pooled across treatment failure			Model 3: Predicting perceived helpfulness of treatment across PTSD patients		
	Prevalence		Multivariate	Prevalence		Multivariate	Prevalence		Multivariate
	Mean/%	(SE)	AOR (95% CI)	Mean/%	(SE)	AOR (95% CI)	Mean/%	(SE)	AOR (95% CI)
Interaction terms between each predictor and historical time									
Treatment delay (years) ^a	6.1	(0.7)	0.98 (0.96-1.00)	6.5	(0.8)	0.97* (0.94-1.00)	7.0	(0.5)	0.97 (0.93-1.00)
χ^2_1			3.77			4.56*			3.66
Treatment type ^b									
Mental health specialist + Psychotherapy	27.8	(1.8)	1.27 (0.67-2.41)	27.7	(1.9)	0.77 (0.34-1.74)	32.3	(1.9)	1.01 (0.39-2.64)
Mental health specialist + Medication	36.5	(2.4)	0.88 (0.27-2.81)	36.4	(2.6)	0.90 (0.33-2.42)	37.0	(2.1)	0.77 (0.19-3.05)
General medical	44.9	(2.5)	0.54 (0.25-1.14)	46.4	(2.7)	2.13 (0.81-5.61)	45.4	(2.1)	0.61 (0.21-1.71)
Complementary/alternative medicine	12.8	(1.5)	0.74 (0.40-1.36)	13.5	(1.6)	0.52 (0.23-1.20)	14.8	(1.6)	0.34* (0.13-0.93)
Human services	15.0	(2.1)	1.00 -	16.2	(2.3)	1.00 -	15.1	(1.9)	1.00 -
χ^2_4			5.96			6.44			5.51
Exactly 2 or more types of treatment	43.1	(2.5)	3.39 (0.79-14.57)	43.3	(2.8)	0.17* (0.05-0.61)	45.0	(2.1)	1.59 (0.32-7.91)
χ^2_1			2.69			7.39*			0.32
χ^2_5			13.60*			33.03*			5.59
Number of lifetime anxiety disorders ^c									
3+ ^c	20.2	(2.2)	1.15 (0.61-2.17)	21.1	(2.2)	0.98 (0.44-2.16)	18.8	(1.9)	1.04 (0.51-2.14)
2 ^c	17.5	(1.9)	0.78 (0.35-1.74)	18.4	(2.1)	1.22 (0.52-2.83)	19.7	(1.9)	1.22 (0.44-3.43)
1 ^c	19.5	(1.8)	1.00 -	18.0	(1.7)	1.00 -	24.0	(1.9)	1.00 -
χ^2_2			0.95			0.27			0.15

TABLE A5 (Continued)

	Model 1: Predicting helpful treatment pooled across professionals seen			Model 2: Predicting persistence pooled across treatment failure			Model 3: Predicting perceived helpfulness of treatment across PTSD patients					
	Prevalence		Multivariate	Prevalence		Multivariate	Prevalence		Multivariate			
	Mean/%	(SE)	AOR	(95% CI)	Mean/%	(SE)	AOR	(95% CI)	Mean/%	(SE)	AOR	(95% CI)
Childhood adversities												
Family dysfunction ^d	16.3	(1.1)	0.48*	(0.30–0.78)	18.9	(1.3)	0.48	(0.21–1.11)	17.8	(1.2)	0.39*	(0.17–0.89)
Other ^e	7.7	(0.7)	0.60	(0.34–1.04)	9.1	(0.9)	0.73	(0.34–1.56)	10.4	(1.0)	0.60	(0.27–1.34)
χ^2_2			13.33*				3.73				6.23*	
Global χ^2_{10}			41.92*				40.80*				23.26*	

Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; PTSD, posttraumatic stress disorder; SE, standard error.

^aTreatment delay (years) = Age at first PTSD treatment – Age at onset of PTSD.

^bTreatment providers: mental health specialists (psychiatrist, psychiatric nurse, psychologist, psychiatric social worker, mental health counselor), primary care providers, human services providers (social worker or counselor in a social services agency, spiritual advisor), and complementary/alternative medicine (other type of healer or self-help group).

^cLifetime anxiety disorders include generalized anxiety disorder, panic disorder, agoraphobia with or without panic disorder, posttraumatic stress disorder, specific phobia and social phobia.

^dFamily dysfunction includes physical abuse, sexual abuse, neglect, parent mental disorder, parent substance use disorder, parent criminal behavior and family violence. Percentages represent the proportions of respondents with one or more of these childhood adversities.

^eOther childhood adversities include parent died, parent divorced, other parent loss, physical illness and economic adversity. Percentages represent the proportions of respondents with one or more of these childhood adversities.

*Significant at .05 level, two-sided test.